At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
CS-7017 +1 moredrug
Likely dose
CS-7017 0.25mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy
In Brief
A Phase 2 clinical trial evaluating CS-7017 and erlotinib for Advanced Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 90 participants across 17 sites in 4 countries.
Detailed Summary
This is a Phase 2 and open-label (subject will know the treatment he or she is receiving) study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study. The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of survival in subjects with advanced non-small cell lung cancer who failed the first treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, India, South Korea, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedApr 2010
Primary CompletionApr 2013
TodayJul 2026
First PostedApr 9, 2010
Enrollment StartMar 1, 2010
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 16.2 years ago
Interventions
CS-7017drug
CS-7017, Two 0.25mg Tablets administered twice daily
erlotinibdrug
Erlotinib; One 150mg tablet administered once daily